Cargando…
Inhaled Antibiotics for Mycobacterial Lung Disease
Mycobacterial lung diseases are an increasing global health concern. Tuberculosis and nontuberculous mycobacteria differ in disease severity, epidemiology, and treatment strategies, but there are also a number of similarities. Pathophysiology and disease progression appear to be relatively similar b...
Autores principales: | Banaschewski, Brandon, Hofmann, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680843/ https://www.ncbi.nlm.nih.gov/pubmed/31331119 http://dx.doi.org/10.3390/pharmaceutics11070352 |
Ejemplares similares
-
The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020) -
Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics
por: Faverio, Paola, et al.
Publicado: (2021) -
Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease
por: Kwon, Yong-Soo, et al.
Publicado: (2016) -
The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
por: Yagi, Kazuma, et al.
Publicado: (2017) -
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
por: Maselli, Diego J., et al.
Publicado: (2017)